APOBEC deaminases-mutases with defensive roles for immunity

Science in China, Series C: Life Sciences

Volumn 52, Issue 10, 2009, Pages 893-902

  Prochnow, Courtney ^a   Bransteitter, Ronda ^a   Chen, Xiao Jiang S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Activation induced cytidine deamination; APOBEC; Class switch recombination; Cytidine deaminase; DNA deamination; Human immunodeficiency virus (HIV); HyperIgM 2 syndrome; Somatic hypermutation

Indexed keywords

AICDA (ACTIVATION INDUCED CYTIDINE DEAMINASE); AICDA (ACTIVATION-INDUCED CYTIDINE DEAMINASE); CYTIDINE DEAMINASE; NUCLEIC ACID;

ADAPTIVE IMMUNITY; ANIMAL; CHEMISTRY; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MULTIGENE FAMILY; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; REVIEW;

ADAPTIVE IMMUNITY; ANIMALS; CYTIDINE DEAMINASE; HUMANS; IMMUNITY, INNATE; MULTIGENE FAMILY; NUCLEIC ACIDS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

DNA VIRUSES; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77749335648     PISSN: 10069305     EISSN: 18622798     Source Type: Journal    
DOI: 10.1007/s11427-009-0133-1     Document Type: Review

References (104)

1. Jarmuz A, Chester A, Bayliss J, et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics, 2002, 79: 285-296.
2. Franca R, Spadari S, Maga G. APOBEC deaminases as cellular antiviral factors: A novel natural host defense mechanism. Med Sci Monit, 2006, 12: RA92-RA98.
3. OhAinle M, Kerns J A, Malik H S, et al. Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J Virol, 2006, 80: 3853-3862.
4. Navarro F, Bollman B, Chen H, et al. Complementary function of the two catalytic domains of APOBEC3G. Virology, 2005, 333: 374-386.
5. Newman E N, Holmes R K, Craig H M, et al. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol, 2005, 15: 166-170.
6. Iwatani Y, Takeuchi H, Strebel K, et al. Biochemical activities of highly purified, catalytically active human APOBEC3G: Correlation with antiviral effect. J Virol, 2006, 80: 5992-6002.
7. Liddament M T, Brown W L, Schumacher A J, et al. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol, 2004, 14: 1385-1391.
8. Bishop K N, Holmes R K, Sheehy A M, et al. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol, 2004, 14: 1392-1396.
9. Bogerd H P, Wiegand H L, Doehle B P, et al. The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology, 2007, 364: 486-493.
10. Okazaki I M, Hiai H, Kakazu N, et al. Constitutive expression of AID leads to tumorigenesis. J Exp Med, 2003, 197: 1173-1181.
11. Kou T, Marusawa H, Kinoshita K, et al. Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. Int J Cancer, 2007, 120: 469-476.
12. Komori J, Marusawa H, Machimoto T, et al. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology, 2008, 47: 888-896.
13. Longerich S, Orelli B J, Martin R W, et al. Brca1 in immunoglobulin gene conversion and somatic hypermutation. DNA Repair (Amst), 2008, 7: 253-266.
14. Marusawa H. Aberrant AID expression and human cancer development. Int J Biochem Cell Biol, 2008, 40: 1399-1402.
15. Matsumoto Y, Marusawa H, Kinoshita K, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med, 2007, 13: 470-476.
16. Morisawa T, Marusawa H, Ueda Y, et al. Organ-specific profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression. Int J Cancer, 2008, 123: 2735-2740.
17. Chester A, Scott J, Anant S, et al. RNA editing: Cytidine to uridine conversion in apolipoprotein B mRNA. Biochim Biophys Acta, 2000, 1494: 1-13.
18. Teng B, Burant C F, Davidson N O. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science, 1993, 260: 1816-1819.
19. Navaratnam N, Morrison J R, Bhattacharya S, et al. The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase. J Biol Chem, 1993, 28: 20709-20712.
20. Petersen-Mahrt S K, Neuberger M S. In vitro deamination of cytosine to uracil in single-stranded DNA by apolipoprotein B editing complex catalytic subunit 1 (APOBEC1). J Biol Chem, 2003, 278: 19583-19586.
21. Anant S, Mukhopadhyay D, Sankaranand V, et al. ARCD-1, an apobec-1-related cytidine deaminase, exerts a dominant negative effect on C to U RNA editing. Am J Cell Physiol, 2001, 281: C1904-1916.
22. Rogozin I B, Basu M K, Jordan K I, et al. APOBEC4, a new member of the AID/APOBEC family of polynucleotide (Deoxy)cytidine deaminases predicted by computational analysis. Cell Cycle, 2005, 4: 1281-1285.
23. Peled J U, Kuang F L, Iglesias-Ussel M D, et al. The biochemistry of somatic hypermutation. Annu Rev Immunol, 2008, 26: 481-511.
24. Schrader C E, Guikema J E, Wu X, et al. The roles of APE1, APE2, DNA polymerase beta and mismatch repair in creating S region DNA breaks during antibody class switch. Philos Trans R Soc Lond B Biol Sci, 2009, 364: 645-652.
25. Muramatsu M, Kinoshita K, Fagarasan S, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell, 2000, 102: 553-563.
26. Neuberger M S, Harris R S, Di Noia J M, et al. Immunity through DNA deamination. Trends Biochem Sci, 2003, 28: 305-312.
27. Bransteitter R, Pham P, Scharff M D, et al. Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc Natl Acad Sci USA, 2003, 100: 4102-4107.
28. Langlois M A, Beale R C L, Conticello S G, et al. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases providing insight into their DNA target site specificities. Nucleic Acids Res, 2005, 33: 1913-1923.
29. Pham P, Bransteitter R, Petruska J, et al. Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature, 2003, 424: 103-107.
30. Imai K, Slupphaug G, Lee W I, et al. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol, 2003, 4: 1023-1028.
31. Revy P, Muto T, Levy Y, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell, 2000, 102: 565-575.
32. Durandy A, Peron S, Fischer A. Hyper-IgM syndromes. Curr Opin Rheumatol, 2006, 18: 369-376.
33. Minegishi Y, Lavoie A, Cunningham-Rundles C, et al. Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome. Clin Immunol, 2000, 97: 203-210.
34. Sheehy A M, Gaddis N C, Choi J D, et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature, 2002, 418: 646-650.
35. Alce T M, Popik W. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J Biol Chem, 2004, 279: 34083-34086.
36. Luo K, Lui B, Xiao Z, et al. Amino-terminal region of the human immunodeficiency virus type 1 nucleo-capsid is required for human APOBEC3G packaging. J Virol, 2004, 78: 11841-11852.
37. Zennou V D, Perez-Caballero D, Gottlinger H, et al. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J Virol, 2004, 78: 12058-12061.
38. Scharfer A, Bogerd H P, Cullen B R. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology, 2004, 328: 163-168.
39. Burnett A, Spearman P. APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J Virol, 2007, 81: 5000-5013.
40. Suspene R, Sommer P, Henry M, et al. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res, 2004, 32: 2421-2429.
41. Yu Q, Konig R, Pillai S, et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol, 2004, 11: 435-442.
42. Guo F, Cen S, Niu M, et al. The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J Virol, 2007, 81: 11322-11331.
43. Iwatani Y, Chan D S B, Wang F, et al. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res, 2007, 35: 7096-7108.
44. Li X-Y, Guo F, Zhang L, et al. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J Biol Chem, 2007, 282: 32065-32074.
45. Luo K, Wang T, Liu B, et al. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol, 2007, 81: 7238-7248.
46. Mbisa J L, Barr R, Thomas J A, et al. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit effects in plus-strand DNA transfer and integration. J Virol, 2007, 81: 7099-7110.
47. Doehle B P, Schafer A, Cullen B R. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology, 2005, 339: 281-288.
48. Gooch B D, Cullen B R. Functional domain organization of human APOBEC3G. Virology, 2008, 379: 118-124.
49. Bourara K, Liegler T J, Grant R M. Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog, 2007, 3: 1477-1485.
50. Dang Y, Wang X, Esselman W J, et al. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol, 2006, 80: 10522-10533.
51. Yu Q, Chen D, Konig R, et al. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem, 2004, 279: 53379-53386.
52. Goila-Gaur R, Khan M A, Miyagi E, et al. Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology, 2007, 4: 61.
53. Miyagi E, Opi S, Takeuchi H, et al. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol, 2007, 81: 13346-13353.
54. Schumacher A J, Hache G, Macduff D A, et al. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol, 2008, 82: 2652-2660.
55. Chen H, Lilley C E, Yu Q, et al. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol, 2006, 16: 480-485.
56. Noguchi C, Ishino H, Tsuge M, et al. G to A hypermutation of hepatitis B virus. Hepatology, 2005, 41: 626-633.
57. Rosler C, Kock J, Kann M, et al. APOBEC-mediated interference with hepadnavirus production. Hepatology, 2005, 42: 310-309.
58. Kock J, Blum H E. Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. J Gen Virol, 2008, 89: 1184-1191.
59. Suspene R, Guetard D, Henry M, et al. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci USA, 2005, 102: 8321-8326.
60. Turelli P, Mangeat B, Jost S, et al. Inhibition of hepatitis B virus replication by APOBEC3G. Science, 2004, 303: 1829.
61. Vartanian J, Guetard D, Henry M, et al. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science, 2008, 320: 230-233.
62. Santiago M L, Montano M, Benitez R, et al. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science, 2008, 321: 1343-1346.
63. Esnault C, Heidmann O, Delebecque F, et al. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature, 2005, 433: 430-433.
64. Bogerd H P, Wiegand H L, Doehle B P, et al. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res, 2006, 34: 89-95.
65. Dutko J A, Schafer A, Kenny A E, et al. Inhibition of yeast LTR retrotransposon by human APOBEC3 cytidine deaminases. Curr Biol, 2005, 15: 661-666.
66. Schumacher A J, Nissley D V, Harris R S. APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc Natl Acad Sci USA, 2005, 102: 9854-9859.
67. Muckenfuss H, Hamdorf M, Held U, et al. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem, 2006, 281: 22161-22172.
68. Bogerd H P, Wiegand H L, Hulme A E, et al. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci USA, 2006, 103: 8780-8785.
69. Stenglein M D, Harris R S. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Biol Chem, 2006, 281: 16837-16841.
70. Chiu Y L, Witkowska H E, Hall S C, et al. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci USA, 2006, 103: 15588-15593.
71. Hulme A E, Bogerd H P, Cullen B R, et al. Selective inhibition of Alu retrotransposition by APOBEC3G. Gene, 2007, 390: 199-205.
72. Chiu Y L, Greene W C. APOBEC3G: an intracellular centurion. Philos Trans R Soc Lond B Biol Sci, 2009, 364: 689-703.
73. Prochnow C, Bransteitter R, Klein M G, et al. The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature, 2007, 445: 447-451.
74. Brar S S, Sacho E J, Tessmer I, et al. Activation-induced deaminase, AID, is catalytically active as a monomer on single-stranded DNA. DNA Repair (Amst), 2008, 7: 77-87.
75. Bhagwat A S, Carpenter M A, Bujnicki J M. Is AID a monomer in solution? DNA Repair (Amst), 2008, 7: 349-350.
76. Chelico L, Goodman M F. A model for oligomeric regulation of APOBEC3G cytosine deaminase-dependent restriction of HIV. J Biol Chem, 2008, 283: 13780-13791.
77. Wedekind J E, Gillilan R, Janda A, et al. Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular ribonucleoprotein particles from dimeric subunits. J Biol Chem, 2006, 281: 38122-38126.
78. Huthoff H, Autore F, Gallois-Montbrun S, et al. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog, 2009, 5: e1000330.
79. Bennett R P, Salter J D, Liu X, et al. APOBEC3G subunits self-associate via the C-terminal deaminase domain. J Biol Chem, 2008, 283: 33329-33336.
80. Holden L G, Prochnow C, Chang P Y, et al. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature, 2008, 456: 121-124.
81. Chen K M, Harjes E, Gross P J, et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature, 2008, 452: 116-119.
82. Bishop K N, Holmes R K, Sheehy A M, et al. APOBEC-mediated editing of viral RNA. Science, 2004, 305: 645.
83. Petit V, Guetard D, Renard M, et al. Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo. J Mol Biol, 2009, 385: 65-78.
84. Mehta A, Kinter M T, Sherman N E, et al. Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA. Mol Cell Biol, 2000, 20: 1846-1854.
85. + T cells. Nature, 2005, 435: 108-114.
86. Furukawa A, Nagata T, Matsugami A, et al. Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. EMBO J, 2009, 28: 440-451.
87. Chelico L, Pham P, Calabrese P, et al. APOBEC3G DNA deaminase acts processively 3′ → 5′ on single-stranded DNA. Nat Struc Mol Biol, 2006, 13: 392-399.
88. Harris R S, Bishop K N, Sheehy A M, et al. DNA deamination mediates innate immunity to retroviral infection. Cell, 2003, 113: 803-809.
89. Conticello S G, Langlois M A, Yang Z, et al. DNA deamination in immunity: AID in the context of its APOBEC relatives. Adv Immunol, 2007, 94: 37-73.
90. Harris R S, Petersen-Mahrt S K, Neuberger M S. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell, 2002, 10: 1247-1253.
91. Chen H, Lilley C E, Yu Q, et al. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol, 2006, 16: 480-485.
92. Kohli R M, Abrams S R, Gajula K S, et al. A portable hotspot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase. J Biol Chem, 2009, 284: 22898-22904.
93. Chelico L, Pham P, Goodman M F. Mechanisms of APOBEC3G-catalyzed processive deamination of deoxycytidine on single-stranded DNA. Nat Struct Mol Biol, 2009, 16: 454-455.
94. Nowarski R, Britan-Rosich E, Shiloach T, et al. Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat Struct Mol Biol, 2008, 15: 1059-1066.
95. Pham P, Bransteitter R, Goodman M F. Reward versus risk: DNA cytidine deaminases triggering immunity and disease. Biochemistry, 2005, 44: 2703-2715.
96. Rada C, Di Noia J M, Neuberger M S. Mismatch recognition and uracil excision provide complementary paths to both Ig switching and the A/T-focused phase of somatic mutation. Mol Cell, 2004, 16: 163-171.
97. Zhu Y, Nonoyama S, Morio T, et al. Type two hyper-IgM syndrome caused by mutation in activation-induced cytidine deaminase. J Med Dent Sci, 2003, 50: 41-46.
98. Basu U, Chaudhuri J, Alpert C, et al. The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation. Nature, 2005, 438: 508-511.
99. Basu U, Chaudhuri J, Phan R T, et al. Regulation of activation induced deaminase via phosphorylation. Adv Exp Med Biol, 2007, 596: 129-137.
100. Pasqualucci L, Kitaura Y, Gu H, et al. PKA-mediated phosphorylation regulates the function of activation-induced deaminase (AID) in B cells. Proc Natl Acad Sci USA, 2006, 103: 395-400.
101. McBride K M, Gazumyan A, Woo E M, et al. Regulation of hypermutation by activation-induced cytidine deaminase phosphorylation. Proc Natl Acad Sci USA, 2006, 103: 8798-8803.
102. Pham P, Smolka M B, Calabrese P, et al. Impact of phosphorylation and phosphorylation-null mutants on the activity and deamination specificity of activation-induced cytidine deaminase. J Biol Chem, 2008, 283: 17428-17439.
103. Arnold K, Bordoli L, Kopp J, et al. The SWISS-MODEL Workspace: A web-based environment for protein structure homolgy modelling. Bioinformatics, 2006, 22: 195-201.
104. DeLano W L. The PyMOL Molecular Graphics System: DeLano Scientific, 2002.